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VALIDATION OF A SOLUBLE INTERLEUKIN-2 RECEPTOR ASSAY FOR THE
DIAGNOSTIC OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INDIAN
CHILDREN
Veronique Dinand, Sakshi Sharma, Nita Radhakrishnan, Anupam
Sachdeva. Pediatric Hematology Oncology and BMT Unit, Sir Ganga Ram
Hospital, New Delhi, India
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a cellular
immune dysregulation caused by underlying genetic defects (Primary) or
triggered by infection, malignancies or rheumatological conditions.
Although raised soluble interleukin-2 receptor (sIL2-R, CD25) has been
suggested as a biomarker, it is not routinely measured in India. The
objective of the present study was to establish an assay and validate the
cut-off value of sIL2-R for the diagnosis of HLH in Indian children.
Methods: Children with persistent fever, organomegaly, cytopenias
with biochemical markers of HLH (fulﬁlling the criteria) were labeled
as cases. Peripheral blood serum of cases and healthy was cry-
opreserved. A double-sandwich enzyme immune assay was used to
measure sIL2-R in a ﬁrst batch of cases and controls. Standards and
samples were run in duplicates. The optimum cutoff value was deter-
mined using ROC curve, and validated in a second batch of suspected
HLH cases and controls.
Results: 74 children were enrolled (28 suspected HLH, 46 controls), with
similar age/ sex distribution. The optimal sIL2R cutoff of 12ng/ml was
found to be equivalent to 2400U/ml in the standardization batch (16 cases/
22 controls). This cut-off in the validation batch (12 suspected cases and 24
controls) conﬁrmed HLH in 11 cases, while it excluded HLH in 1 possible
case. sIL2-R was higher in familial (n¼8; median 4500U/ml [IQR:
3,305e4,183]) than HLH secondary to infective trigger, malignancy or
SOJIA (n¼19; median 4500U/ml [IQR: 3,305e4,183] vs. 2,810U/ml
[1,655e3,720], p<0.001). On analyzing the prognostic signiﬁcance of sIL2-
R, sIL2- R3200U/ml was signiﬁcantly associated with mortality (85.7% vs.
20.0% in patients with sIL2- R<3200, p¼0.003).
Conclusion: A simple sIL2-R assay was successfully established. sIL2-R is
higher in primary HLH and can aid in diagnosis and predict mortality
especially when molecular diagnosis is delayed or not available. Normal




FOLATE/VITAMIN B12 DEFICIENCY IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA: BREAKING THE MYTH
Sanjeev Khera, Amita Trehan, Savita Attri, Richa Jain, Deepak
Bansal. PGIMER, Chandigarh, India
Background: VitaminB12& Folicacid (FA) supplementation inpatientswith
a malignancy are considered counter-productive by making the cell stroma
conducive to the proliferation of the malignant clone. Patients in lower
middle income countries (LMIC's) have greater incidence of malnutrition
with vitamin deﬁciencies. The need for refraining from supplementation of
FA to patients with a malignancy in LMIC's has been questioned.
Aim: To evaluate the incidence of vitamin B12/FA deﬁciency in children on
therapy for Acute Lymphoblastic Leukemia (ALL).
Materials & Methods: Children with ALL on therapy were randomly
evaluated for serum B12 and folate levels. Serum B12 < 211pg/ml and
serum Folate < 2 ng/ml were taken as deﬁcient levels. Deﬁciency status
was correlated to under-nutrition. Weight for age < -2z score was taken as
under-nutrition (WHO).
Results: 85 children with mean age 6.8 yrs (6.03-7.73), including 50 on
maintenance and 35 on induction/consolidation chemotherapy were
evaluated.50 age and sex matched controls were also evaluated.
Induction/ Consolidation: 7/35 children (20%) were undernourished.
Mean B12 levels were 330.4pg/ml (227.76-345.84), with 11 (32%) beingB12 deﬁcient. 2/11 patients were undernourished. Only1 child had folate
deﬁciency, the mean levels being 8.55ng/ml (5.85-11.13).
Maintenance Therapy: 14 children (28%) were malnourished. Mean B12
levels were 500.56pg/ml (419.74-581.38). B12 deﬁciency was seen in 5
(10%) patients, with 3/5 being under-nourished. Mean Folate levels were
6.61ng/ml (5.56-7.66), deﬁciency being seen in 4 (8%) patients 3 of whom
were under-nourished.
There was no difference of B12 & Folate levels when sex, T/B cell ALL,
standard risk Vs high/intermediate risk ALL were compared. Undernour-
ished children had signiﬁcantly low levels of Folate (4.59 Vs 7.4; p¼0.0139).
This difference was not observed with B12 levels.
50 age/sex matched children taken as controls did not have either
deﬁciency.
Conclusion: Under-nutrition in India is 45.9% as per National Family
Health Survey (NFHS)-3 with reported prevalence of B12& FA deﬁciency in
the general population to be 7-33% and 20-33%; with a even higher
prevalence in the undernourished. 25% of our cohort had under-nutrition.
We had 5.8% with Folate & 20% childrenwith B12 deﬁciency. Patients with
co existing malnutrition had greater B12/FA deﬁciency. Higher B12 deﬁ-
ciency in induction/consolidation which may be due to higher demands or
drug interactions needs further evaluation. A larger cohort would help
conclude and nullify the hypothesis of FA supplementation to cancer pa-
tient in LMIC's. Under-nutrition in LMIC's remains the main issue to be
tackled.
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INVESTIGATING HEPATITIS B IMMUNITY IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA PRESENTING AT A TERTIARY CANCER
CARE CENTRE
V.R. Prasanth, T. Priyakumary, Parukuttyamma Kusumakumary. Division of
Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala,
India
Background: Hepatitis B is a dreaded infectious disease and one of the
major global public health problems and is the tenth leading cause of
death. The global disease burden is staggering with about two billion
people acutely infected and nearly 350 million chronically infected with
hepatitis B virus (HBV). In India, the prevalence of hepatitis B surface an-
tigen (HBsAg) among the general population ranges from 2% to 8%, placing
India in an intermediate HBV endemicity zone. Our country has over 50
million cases making it the second largest global pool of chronic HBV in-
fections. Waning of vaccine induced immunity leaves people at risk of
acquiring hepatitis B infection in settings where the prevalence of infec-
tion is high .Vaccine- induced seroprotection (AntiHBs) is a useful surro-
gate of vaccine efﬁcacy.
Objective: To assess immunity to Hepatitis B virus at initial presentation in
children with newly diagnosed ALL treated in the Paediatric Oncology
Division, Regional Cancer Centre, Thiruvanathapuram, Kerala.
Methods: Children (0-14 years) with newly diagnosed ALL treated be-
tween January 2016 to August 2016 were evaluated. Data regarding pri-
mary HB immunization were collected from the immunization
card.AntiHBsAg titers were done at presentation using Enzyme Linked
Fluoroscent Assay method using VIDAS (Bio-Merieux).Patients were clas-
siﬁed as immune (antibody levels to hepatitis B surface antigen (antiHBs)
>100mIU/ml), lowimmune (antiHBs10-100mIU/ml) and not immune
(antiHBs<10 mIU/ml).
Results: Of the 109 children included (median age 5.6 years, M:F-
1.5:1),75(68.8%) children had protective antiHBstitres (>10IU/L),34(31.2%)
children had no immunity to hepatitis B.Of the 75 childrenwith protective
antiHBstitres 37 children (49.33%) had low immune antiHBstitres (10-
100mIU/ml) and 38 children (50.66%) had immune antiHBstitres> 100
mIu/ml.Nopatients had active hepatitis B infection (hepatitis B surface
antigenpositive) at presentation.
Discussion: Acute Lymphoblastic Leukemia (ALL) is the most common
malignant disease in children.The more intensive treatment and risk
stratiﬁcation adopted over the last decade have resulted in an improve-
ment in the survival rate, which, in many cases, reaches 90%.Both the
illness and treatment affect the immune system. Immune competence
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due to the reduction of serum antibody titers gained from previous
immunizations.Children are at an high risk for developing hepatitis B virus
(HBV) infection from immunosuppression secondary to chemotherapy and
multiple blood transfusions. Most of the children infected with HBV
develop chronic hepatitis. An Indian study by Jacob Puliyel et al, showed at
6 years of age, protective levels of anti-HBs antibody (>10 mlU/mL) were
present only in about 59% of those immunized. By 11 years, only 13% had
protective levels. The increasing potential for the cure of childhood ALL
emphasizes the need for a method of reducing hepatitis and its sequelae in
these children. Our study revealed only 68.8% children with newly diag-
nosed ALL had protective antiHBstitres (>10IU/L), while 31.2% children had
no immunity tohepatitis B despite presumed vaccination as part of the UIP
schedule.
Conclusion: A signiﬁcant number of newly diagnosed children with ALL
lack protective anti HBs titres despite being vaccinated according to Uni-
versal Immunization Programme and Combined passive active immuni-
sation should be considered for them.
LM-1_V1.3
CLINICAL PROFILE AND OUTCOME OF EARLY T-PRECURSOR (ETP)
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN A TERTIARY CARE
CANCER CENTRE
Cheriyalinkal Parambil Badira, Tandon Sneha, Thacker Nirav, P.G.
Subramaniam, Tembhare Prashant, Gujral Sumeet, Patkar Nikhil, Narula
Gaurav, Arora Brijesh, Maya Prasad, Banavali Shripad. Tata Memorial
Hospital, Mumbai, India
E-mail address: badiracp@yahoo.co.in (C.P. Badira).
Introduction: ETPALL is a recently well described high-risk subset of T-ALL
with early differentiation arrest and showing features overlappingwith AML
andwith poor prognosis which can potentially be improvedwith intensiﬁed
induction using dexamethasone and high-dose L-asparaginase. We audited
our experience with ETP-ALL for its clinical proﬁle and outcome.
Methods: We retrospectively evaluated all children (<15yrs) diagnosed
with ETP-ALL or Near ETP-ALL from January 2012 to December 2015. All
were treated with institutional ALL protocol (modiﬁed MCP-841) with
4drug induction incorporating prednisolone and high dose Ara-C in
consolidation (16g/m2). From June 2014, the protocol was amended by
substituting prednisolone with dexamethasone (10mg/m2/dy) in induc-
tion along with higher intensity of L-asparaginase (10000 U/m2/dose).
Results: T-ALL was diagnosed in 283 children, of whom 34 were ETP-ALL
(14%) and 5 were Near ETP-ALL (1.7%): Median age was -13 years; Male : fe-
male- 2.5:1; Bulky disease-18%; mediastinal mass-12.8%; median WBC
count- 10.1x109/mm3; Hyperleucocytosis (>100x109mm3)- 10%; No CNS
involvement.DemographicsofT-ALL insameperiod:medianage-9yrs;male:
Female 4:1; medianWBC count- 50x109 /mm3; hyperleucocytosis-36.7%.
Of 39 childrenwith ETP-ALL, 32 took treatment. At a median follow-up of 10
months (range3 -50months), the2-yearOS is52.5%andEFS is53.7%.Median
OS is not reached as yet. Of 32 patients, 15 received prednisolone based in-
duction and17 received dexamethasonebased intensive induction. Overall 8
(25%) died during induction therapy (dexamethasone arm e 29.4%, pred-
nisolone arm -20%). Of the evaluable 24 patients (dexamethasone arm-12,
prednisolone arm-12),18 patients (75%) achieved complete morphological
remission at the end of induction (dexamethasone arm-58%, prednisolone
arm-92%, p¼0.15). Of 14 patients whose Minimal Residual Disease (MRD)
datawere available (12 of whom received dexamethasone based induction),
5 patients were MRD negative post induction (35.7%), and corresponding
morphological remission was seen in 9 (50%). Of the 9 patients who were
MRD positive post induction,7 (78%) cleared MRD post subsequent cycles
.There has been no relapse so far and the projected 2-year DFS is 89%.
Conclusions: ETP-ALL constituted 16% of T-ALL children. Children with
ETP-ALL had higher median age, low disease burden at presentation and
infrequent CNS involvement. The disease free survival with this protocol
using high dose cytarabine based consolidation is good. However inten-
siﬁcation of therapy in induction did not improve remission rates but led to
higher induction mortality and poorer overall outcome in our low-middle
income setting.LM-1_V1.4
TOXICITY PROFILE OF L-ASPARAGINASE IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKAEMIA e SINGLE CENTRE EXPERIENCE
Rachel Priyanka Pulla, Lakshmi Priya, A. Arun Shriram, Julius Xavior
Scott, M.S. Latha, Ravishankar, Meriton Stanley. Sri Ramachandra
Medical College and Research Institute, Chennai, Porur 600116, India
Introduction: Acute lymphoblastic leukemia (ALL) is a hematologic ma-
lignancy that predominantly occurs in children between 2 and 10 years of
age. L-asparaginase is an integral component of treatment for patients
with ALL and since its introduction into pediatric treatment protocols in
the 1960s, survival rates in children have progressively risen to nearly 90%.
The effects of L-asparaginase on hemostasis during induction chemo-
therapy are less deﬁned in children. These hemostatic modiﬁcations
induced by L-asparaginase are relatively rare and mild in children, but
their incidence has not yet beenwell evaluated and their Toxicity proﬁle in
Indian children is very rarely documented.
Aims and Objectives: Primary Objective: To demonstrate the toxicity
proﬁle of L- Asparaginase in childrenwith Acute Lymphoblastic Leukaemia
speciﬁcally to evaluate hyperlipidemia and changes in coagulation and
thrombotic risk.
Secondary Objective: To study the differences in toxicities of L-Aspar-
aginase between the two types of L-Asparaginase (E coli and Pegylated).
Methodology:
 Children after the diagnosis with acute lymphoblastic leukemia under-
went baseline investigations with Liver function tests, Lipase, PT, PTT, INR,
Random blood sugar and Lipid proﬁle prior to the onset of treatment and
thereafter weekly during induction and re induction periods.
 Antithrombin III and ﬁbrinogen were done twice during induction (day
15 and 29) and once during reinduction therapy (on day 22).
 Demographic data, clinical details, details of diagnosis, Laboratory values
were recorded in a proforma. Analyzed data were analysed using SPSS 16.
The study was approved by our institution ethics committee.
 The study was funded by Tiara Hemophilia Cancer Foundation, NGO
supporting in Chennai supports pediatric cancer researches.
Results: 80 cases were included in this study of which 53 were males and
27 were females. Pre B cell leukemia were 57 and T cell Leukemia were 23.
Type of L- Asparagine used were E coli Asparaginase (n-50) and Pegylated
L Asparaginase (n-30). Complications seen were elevated lipase level
without any evidence of clinical pancreatitis 12.5%, Hyperglycemia 12.5%,
hyperlipidemia 10%, Thrombosis 2.5%, Allergies 5.6%, elevated PT/PTT 10%;
Low AT 3 (15.5%) and low ﬁbrinogen (16.5%).
There is no Statistical difference between the two groups of L-Asparginase
studied, however increase side effects were noted in Ecoli Asparaginase
group.
Conclusion:
 Asparaginase is a critical component of all pediatric ALL protocols, with
many protocols incorporating prolonged and high intensity L-Aspar-
aginase treatment, it is important that our Indian data be available of all
potential treatment-related toxicities.
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HYPERGLYCEMIA DURING INDUCTION CHEMOTHERAPY OF PEDIATRIC
ACUTE LYMPHOBLASTIC LEUKEMIA
Shwetha Seetharam, T. Priyakumari, P. Kusumakumary. Division of Pediatric
Oncology, Regional Cancer Center, Thiruvanathapuram, Kerala, India
Introduction: Hyperglycemia occurs in about 10-16% of children during
induction chemotherapy for acute lymphoblastic leukemia (ALL), which
includes steroids and L asparaginase. Patients may present with diabetic
ketoacidosis or non-ketotic hyperglycemic hyperosmolar syndrome. Hy-
perglycemia has also been reported to suppress immune function by in-
hibition of endogenous production of interleukins 2, 6 and 10 and
uncontrolled diabetes is a risk factor for developing invasive fungal
infections.
Materials and Methods: This study analysed the incidence and outcome
of hyperglycemia in pediatric patients (0-14yrs) during induction
